Genomic signature for oligometastatic disease in non-small cell lung cancer patients with brain metastases

Elucidation of a genomic signature for extracranial oligometastatic disease derived from non-invasive liquid biopsy appears feasible for NSCLC patients. Patients with this signature exhibited higher rates of early oligoprogression. External validation could lead to a biomarker that has the potential to direct local therapies in oligometastatic patients.

Authors

Institutions

Publication Details

Journal
Frontiers in Endocrinology
Published
2024-09-17
DOI
https://doi.org/10.3389/fendo.2024.1364021
Citations
2
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.84
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Genomic signature for oligometastatic disease in non-small cell lung cancer patients with brain metastases

Christopher T. Whitlow, Ralph B. D’Agostino, Fei Xing, Jing Su et al.
2 citations
Frontiers in Endocrinology
Lung Cancer Treatments and Mutations
0.84
article

Genomic signature for oligometastatic disease in non-small cell lung cancer patients with brain metastases

Christopher T. Whitlow, Ralph B. D’Agostino, Fei Xing, Jing Su, Michael Farris, Wencheng Li, Thomas Lycan, Jimmy Ruiz, W. Jeffrey Petty, Adrian W. Laxton, Michael D. Chan, Christina K. Cramer, Stephen B. Tatter, Margaret Smith, Mohammed Abdulhaleem, John Hunting, Ariel R. Choi, Jaclyn J. White, Yuezhu Wang
article en
2 citations

Abstract

Elucidation of a genomic signature for extracranial oligometastatic disease derived from non-invasive liquid biopsy appears feasible for NSCLC patients. Patients with this signature exhibited higher rates of early oligoprogression. External validation could lead to a biomarker that has the potential to direct local therapies in oligometastatic patients.

Frontiers in EndocrinologyVol. 15
Indiana University School of Medicine, Wake Forest University (US), Indiana University – Purdue University Indianapolis (US)
Good health and well-being
Openalex Percentile: Top 24%
Lung Cancer Treatments and Mutations
0.84
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Genomic signature for oligometastatic disease in non-small cell lung cancer patients with brain metastases — Christopher T. Whitlow, Ralph B. D’Agostino, et al. · Frontiers in Endocrinology (2024) | TGRS Research Map | TGRS